Hyperbaric oxygen therapy for the treatment of children and youth with Autism Spectrum Disorders: An evidence-based systematic review / Cynthia GOLDFARB in Research in Autism Spectrum Disorders, 29-30 (September–October 2016)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 29-30 (September–October 2016) . - p.1-7 Titre : Hyperbaric oxygen therapy for the treatment of children and youth with Autism Spectrum Disorders: An evidence-based systematic review Type de document : texte imprimé Auteurs : Cynthia GOLDFARB, Auteur ; Lisa GENORE, Auteur ; Carolyn HUNT, Auteur ; Janine FLANAGAN, Auteur ; Mark HANDLEY-DERRY, Auteur ; Anita JETHWA, Auteur ; Nicola JONES-STOKREEF, Auteur ; S.M.L. KIRKPATRICK, Auteur ; A. RICHARDS, Auteur ; Lillian ROJNICA, Auteur ; Clive SCHWARTZ, Auteur ; David SHAWN, Auteur ; Diann SUPERINA-BELL, Auteur ; Elizabeth YOUNG, Auteur ; Evdokia ANAGNOSTOU, Auteur Article en page(s) : p.1-7 Langues : Anglais (eng) Mots-clés : Autism  Hyperbaric oxygen therapy  Treatment  Review Index. décimale : PER Périodiques Résumé : AbstractBackground Autism Spectrum Disorder (ASD) is a common disorder that has a complex and heterogeneous etiology. Some evidence suggests that inflammation and oxidative stress may have a pathophysiological link. Hyperbaric Oxygen Therapy (HBOT) has been proposed as a possible therapy. Because HBOT is an expensive treatment with significant commercial opportunity, it is essential for it to have a research evidence base prior to widespread use. Objective To conduct a systematic review of the literature evaluating the clinical impact of HBOT on behavior and development in ASD with a view to inform practice. Methods A literature search of electronic scientific databases focusing on clinical outcomes of HBOT in ASD was performed. Articles meeting inclusion criteria were independently assessed by reviewers and were classified according to the American Academy of Neurology Guidelines. Recommendations were made based on the evidence. Results Five articles were reviewed with data extraction. Based on the AAN Classification of Recommendations the data supported a rating of “A”, indicating that HBOT is not effective for treating children and youth with ASD. Conclusions Current evidence does not support HBOT as an effective treatment for children and youth with ASD. En ligne : http://dx.doi.org/10.1016/j.rasd.2016.05.004 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=292 [article] Hyperbaric oxygen therapy for the treatment of children and youth with Autism Spectrum Disorders: An evidence-based systematic review [texte imprimé] / Cynthia GOLDFARB, Auteur ; Lisa GENORE, Auteur ; Carolyn HUNT, Auteur ; Janine FLANAGAN, Auteur ; Mark HANDLEY-DERRY, Auteur ; Anita JETHWA, Auteur ; Nicola JONES-STOKREEF, Auteur ; S.M.L. KIRKPATRICK, Auteur ; A. RICHARDS, Auteur ; Lillian ROJNICA, Auteur ; Clive SCHWARTZ, Auteur ; David SHAWN, Auteur ; Diann SUPERINA-BELL, Auteur ; Elizabeth YOUNG, Auteur ; Evdokia ANAGNOSTOU, Auteur . - p.1-7. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 29-30 (September–October 2016) . - p.1-7 Mots-clés : Autism  Hyperbaric oxygen therapy  Treatment  Review Index. décimale : PER Périodiques Résumé : AbstractBackground Autism Spectrum Disorder (ASD) is a common disorder that has a complex and heterogeneous etiology. Some evidence suggests that inflammation and oxidative stress may have a pathophysiological link. Hyperbaric Oxygen Therapy (HBOT) has been proposed as a possible therapy. Because HBOT is an expensive treatment with significant commercial opportunity, it is essential for it to have a research evidence base prior to widespread use. Objective To conduct a systematic review of the literature evaluating the clinical impact of HBOT on behavior and development in ASD with a view to inform practice. Methods A literature search of electronic scientific databases focusing on clinical outcomes of HBOT in ASD was performed. Articles meeting inclusion criteria were independently assessed by reviewers and were classified according to the American Academy of Neurology Guidelines. Recommendations were made based on the evidence. Results Five articles were reviewed with data extraction. Based on the AAN Classification of Recommendations the data supported a rating of “A”, indicating that HBOT is not effective for treating children and youth with ASD. Conclusions Current evidence does not support HBOT as an effective treatment for children and youth with ASD. En ligne : http://dx.doi.org/10.1016/j.rasd.2016.05.004 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=292

A pilot dose finding study of pioglitazone in autistic children / Lucia CAPANO in Molecular Autism, 9 (2018)  

Public ISBD [article]  inMolecular Autism > 9 (2018) . - 59p. Titre : A pilot dose finding study of pioglitazone in autistic children Type de document : texte imprimé Auteurs : Lucia CAPANO, Auteur ; Annie DUPUIS, Auteur ; Jessica BRIAN, Auteur ; Deepali MANKAD, Auteur ; Lisa GENORE, Auteur ; Rianne HASTIE ADAMS, Auteur ; Sharon SMILE, Auteur ; Toni LUI, Auteur ; Dina ODROBINA, Auteur ; Jane A. FOSTER, Auteur ; Evdokia ANAGNOSTOU, Auteur Article en page(s) : 59p. Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Clinical trial  Cytokines  Drug therapy  Efficacy  Inflammation  Maximum tolerated dose (MTD)  Physiological effects of drugs  Pioglitazone  Safety profile  Treatment Index. décimale : PER Périodiques Résumé : Background: Pioglitazone is a promising compound for treatment of core autism spectrum disorder (ASD) symptoms as it targets multiple relevant pathways, including immune system alterations. Objective: This pilot study aimed to elucidate the maximum tolerated dose, safety, preliminary evidence of efficacy, and appropriate outcome measures in autistic children ages 5-12 years old. Methods: We conducted a 16-week prospective cohort, single blind, single arm, 2-week placebo run-in, dose-finding study of pioglitazone. Twenty-five participants completed treatment. A modified dose finding method was used to determine safety and dose response among three dose levels: 0.25 mg/kg, 0.5 mg/kg, and 0.75 mg/kg once daily. Results: Maximum tolerated dose: there were no serious adverse events (SAEs) and as such the maximum tolerated dose within the range tested was 0.75 mg/Kg once daily.Safety: overall, pioglitazone was well tolerated. Two participants discontinued intervention due to perceived non-efficacy and one due to the inability to tolerate interim blood work. Three participants experienced mild neutropenia.Early evidence of efficacy: statistically significant improvement was observed in social withdrawal, repetitive behaviors, and externalizing behaviors as measured by the Aberrant Behavior Checklist (ABC), Child Yale-Brown Obsessive Compulsive Scale (CY-BOCS), and Repetitive Behavior Scale-Revised (RBS-R). Forty-six percent of those enrolled were deemed to be global responders. Conclusions and relevance: Pioglitazone is well-tolerated and shows a potential signal in measures of social withdrawal, repetitive, and externalizing behaviors. Randomized controlled trials using the confirmed dose are warranted. Trial registration: ClinicalTrials.gov, NCT01205282. Registration date: September 20, 2010. En ligne : https://dx.doi.org/10.1186/s13229-018-0241-5 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=371 [article] A pilot dose finding study of pioglitazone in autistic children [texte imprimé] / Lucia CAPANO, Auteur ; Annie DUPUIS, Auteur ; Jessica BRIAN, Auteur ; Deepali MANKAD, Auteur ; Lisa GENORE, Auteur ; Rianne HASTIE ADAMS, Auteur ; Sharon SMILE, Auteur ; Toni LUI, Auteur ; Dina ODROBINA, Auteur ; Jane A. FOSTER, Auteur ; Evdokia ANAGNOSTOU, Auteur . - 59p. Langues : Anglais (eng) in Molecular Autism > 9 (2018) . - 59p. Mots-clés : Autism spectrum disorder  Clinical trial  Cytokines  Drug therapy  Efficacy  Inflammation  Maximum tolerated dose (MTD)  Physiological effects of drugs  Pioglitazone  Safety profile  Treatment Index. décimale : PER Périodiques Résumé : Background: Pioglitazone is a promising compound for treatment of core autism spectrum disorder (ASD) symptoms as it targets multiple relevant pathways, including immune system alterations. Objective: This pilot study aimed to elucidate the maximum tolerated dose, safety, preliminary evidence of efficacy, and appropriate outcome measures in autistic children ages 5-12 years old. Methods: We conducted a 16-week prospective cohort, single blind, single arm, 2-week placebo run-in, dose-finding study of pioglitazone. Twenty-five participants completed treatment. A modified dose finding method was used to determine safety and dose response among three dose levels: 0.25 mg/kg, 0.5 mg/kg, and 0.75 mg/kg once daily. Results: Maximum tolerated dose: there were no serious adverse events (SAEs) and as such the maximum tolerated dose within the range tested was 0.75 mg/Kg once daily.Safety: overall, pioglitazone was well tolerated. Two participants discontinued intervention due to perceived non-efficacy and one due to the inability to tolerate interim blood work. Three participants experienced mild neutropenia.Early evidence of efficacy: statistically significant improvement was observed in social withdrawal, repetitive behaviors, and externalizing behaviors as measured by the Aberrant Behavior Checklist (ABC), Child Yale-Brown Obsessive Compulsive Scale (CY-BOCS), and Repetitive Behavior Scale-Revised (RBS-R). Forty-six percent of those enrolled were deemed to be global responders. Conclusions and relevance: Pioglitazone is well-tolerated and shows a potential signal in measures of social withdrawal, repetitive, and externalizing behaviors. Randomized controlled trials using the confirmed dose are warranted. Trial registration: ClinicalTrials.gov, NCT01205282. Registration date: September 20, 2010. En ligne : https://dx.doi.org/10.1186/s13229-018-0241-5 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=371

A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism / Deepali MANKAD in Molecular Autism, (March 2015)  

Public ISBD [article]  inMolecular Autism > (March 2015) . - p.1-11 Titre : A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism Type de document : texte imprimé Auteurs : Deepali MANKAD, Auteur ; Annie DUPUIS, Auteur ; Sharon SMILE, Auteur ; Wendy ROBERTS, Auteur ; Jessica BRIAN, Auteur ; Toni LUI, Auteur ; Lisa GENORE, Auteur ; Dina ZAGHLOUL, Auteur ; Alana IABONI, Auteur ; Peggy Margaret A. MARCON, Auteur ; Evdokia ANAGNOSTOU, Auteur Article en page(s) : p.1-11 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Autism spectrum disorder (ASD) is a neurodevelopmental disorder affecting more than 1% of children. It is characterized by social communication deficits and repetitive behaviors/restricted interests. In the absence of any medications known to improve core symptom domains, parents often use complementary alternative treatments, including omega-3 fatty acid supplements. En ligne : http://dx.doi.org/10.1186/s13229-015-0010-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=277 [article] A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism [texte imprimé] / Deepali MANKAD, Auteur ; Annie DUPUIS, Auteur ; Sharon SMILE, Auteur ; Wendy ROBERTS, Auteur ; Jessica BRIAN, Auteur ; Toni LUI, Auteur ; Lisa GENORE, Auteur ; Dina ZAGHLOUL, Auteur ; Alana IABONI, Auteur ; Peggy Margaret A. MARCON, Auteur ; Evdokia ANAGNOSTOU, Auteur . - p.1-11. Langues : Anglais (eng) in Molecular Autism > (March 2015) . - p.1-11 Index. décimale : PER Périodiques Résumé : Autism spectrum disorder (ASD) is a neurodevelopmental disorder affecting more than 1% of children. It is characterized by social communication deficits and repetitive behaviors/restricted interests. In the absence of any medications known to improve core symptom domains, parents often use complementary alternative treatments, including omega-3 fatty acid supplements. En ligne : http://dx.doi.org/10.1186/s13229-015-0010-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=277

---

1 (1 - 3 / 3) Par page : 25 50 100 200